[35] Medical uses [edit] European Union [edit] In the European Union, semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, [16] [17] in addition to other medicinal products for the treatment of diabetes
People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use GLP-1 medications
206,220,221 Given that endoplasmic reticulum stress, impaired autophagy and proliferation, and increased apoptosis are all suggested to promote islet beta-cell pathology in T2D, and the findings that GLP-1R activation can influence all of these give GLP-1 and its analogues a role beyond just enhancing insulin secretion
Ozempic, which is a brand name for a drug called semaglutide, is whats known as a GLP-1 receptor agonist, meaning it mimics the action of GLP-1 2
Semaglutide (February 11, 2024) Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation (May 17, 2025) OZEMPIC (semaglutide) injection, for subcutaneous use
A healthcare provider should be consulted before changing your Ozempic dose
